(170) designed engineered exosomes with surfaces carrying SIRPα, disrupting the CD47-SIRPα interaction between cancer cells and macrophages, enhancing the efficiency of phagocytosis of tumor cells. This evidence concerns the gene SIRPA and neoplasm.